# Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

> **NCT06727721** · PHASE2 · RECRUITING · sponsor: **Lu jin ，MD** · enrollment: 10 (estimated)

## Conditions studied

- Diabetes
- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** mesenchymal stem cells with OCN-19
- **BIOLOGICAL:** Mesenchymal stem cells
- **BIOLOGICAL:** albumin injection

## Key facts

- **NCT ID:** NCT06727721
- **Lead sponsor:** Lu jin ，MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-06
- **Primary completion:** 2028-12-12
- **Final completion:** 2029-12-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727721, "Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06727721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*